Microbiome Drug Development Milestones

There are currently two drugs approved by the FDA for the treatment of recurrent CDI (rCDI): REBYOTA and VOWST. Our Beacon Microbiome team have explored a decades worth of data to provide an overview of the key milestones for these two Microbiome approvals. The infographic, that is now available to download, includes a timeline of trial start and end dates, trial updates, key publications and top news stories.

Microbiome Drug Development Milestones Infographic

What’s covered in the infographic:

  • Overview of the use of FMT therapies for the prevention of CDI and CDI recurrence
  • Timeline of key milestones for both REBYOTA and VOWST
  • Predicted milestones

You May Also Be Interested In…

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more

Menu
Search Icon
Close Icon
Search